CJ 30044Alternative Names: CJ-30044
Latest Information Update: 01 Apr 2016
At a glance
- Originator CJ Cheiljedang Corp.
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 01 May 2013 CJ Cheiljedang Corp. completes a phase I trial in Healthy volunteers in South Korea (NCT01925313)
- 01 Dec 2012 Phase-I clinical trials in Undefined indication (in volunteers) in South Korea (PO)